Nanotechnology & Drug Delivery Systems

Dr. Boyce's lab develops protease-cleavable linkers for peptide prodrugs and antibody-drug conjugates (ADCs) to minimize neutropenia, a common side effect for FDA-approved protease-cleavable ADCs due to premature drug release. The Boyce lab designs biomolecular prodrugs to combat cancer resistance in ccRCC, ovarian, and breast cancers, and focuses on the chemical synthesis, medicinal chemistry optimization, and target evaluation of natural product classes with rare selectivity against cancer.

His lab's research interests focus on protease-activated prodrug development, prodrug linker optimization for cancer therapeutics, biomolecular prodrug development to combat cancer resistance, chemical synthesis of natural product analogs with rare selectivity against cancer, and synthesis of photoaffinity probes for target ID.

Dr. Cocucci studies basic mechanisms of membrane trafficking and is interested in how these processes deviate during cancer development when compared to normal cells. His research adopts multiple techniques, including traditional biochemistry, cell biology, and high resolution fluorescent live cell microscopy. Dr. Cocucci’s goal is to define novel targets for cancer therapy and to improve drug delivery, studying the internalization pathways and the mechanisms of endosomal escape adopted by artificial and biological nanovectors.

Dr. Guo works on both basic research and its subsequent practical applications, focusing on understanding the mechanisms and assembly of viral DNA packaging motor, and using components of the biomotor for various applications. By applying interdisciplinary approaches including chemistry, biophysics, biochemistry, nanotechnology, bioengineering, molecular biology, cell biology, computer modeling, and pharmaceutical sciences, Dr. Guo studies RNA, DNA and proteins and their interaction.

Dr. Guo’s current project areas are:

RNA nanotechnology and its application for the delivery of siRNA/miRNA/drug for the treatment of cancers, viral infection, and genetic diseases
Nanobiotechnology, including structure, function and mechanism of Phi29 DNA-packaging nanomotor
Single molecule imaging and optical instrumentation to study the interaction of RNA, DNA, and protein
Single pore technology for DNA sequencing, macromolecule detection, and disease diagnosis, using channels of variety of viral DNA packaging motors

Dr. Lee's lab is focused on targeted drug delivery systems based on nanoparticles. Nanoparticles can serve as carriers of therapeutic agents, including nucleic acids such as siRNA, miRNA and anti-miRs, and facilitate their therapeutic delivery. The lab's effort is focused on improving nanoparticle composition based on rational design and directed at clinical applications. Ongoing projects include developing miR-targeting lipid nanoparticles and targeted chemotherapeutic drug formulations and bioconjugates for therapy of solid tumors, leukemias, diabetic wounds, and other diseases.